Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

CJC-1295 vs ipamorelin

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors CJC-1295

CJC-1295 has human data that ipamorelin lacks: a single injection raised growth hormone 2 to 10 fold for 6 or more days and IGF-1 1.5 to 3 fold for 9 to 11 days in two small randomized trials in healthy adults. Ipamorelin's human data are one small IV pharmacology study showing growth hormone release in healthy men, and its only randomized trial, for postoperative ileus, was negative. Legally they are in the same place: neither was ever approved, both were placed on FDA's 503A Category 2 list in 2023, both 503A nominations were withdrawn, and both are prohibited in sport.

Verified: Verified Sep 30, 2026
CJC-1295 / IpamorelinSponsoredFrom Bodybuilding Peptides

Which is better, CJC-1295 or ipamorelin?

Both are graded human RCT, so the grade does not separate them. CJC-1295's randomized, placebo controlled pharmacology trials showed sustained GH and IGF-1 increases after an injection under the skin, while ipamorelin's one randomized, placebo controlled trial tested intravenous dosing after bowel surgery and found no benefit, and its growth hormone data in people are a single infusion study in 40 healthy men. The win is narrow: CJC-1295's trials measured hormones, not any clinical benefit, FDA cited increased heart rate and a systemic vasodilatory reaction among its serious adverse events, and both share the same no-lawful-compounding status. No trial has tested either drug, or the popular blend, for body composition. [1] [2] [4] [5] [6] [9]

How do CJC-1295 and ipamorelin compare?

CJC-1295 and Ipamorelin compared by dimension
DimensionCJC-1295FavoredIpamorelin
Mechanism [3] [5]GHRH(1-29) analog with four stabilizing substitutions and a drug affinity complex that binds albumin; acts on the pituitary GHRH receptor.Pentapeptide ghrelin receptor (GHS-R1a) agonist; releases GH through a pathway separate from GHRH.
Duration of action [1] [5]Half life 5.8 to 8.1 days after subcutaneous injection; one dose raised IGF-1 for 9 to 11 days.Short acting; no human pharmacokinetic publication for subcutaneous use. Animal ED50 studies used intravenous dosing.
Note: The product sold as CJC-1295 without DAC (modified GRF 1-29) lacks the albumin linker, has a half life of about 30 minutes, and has no published human trials.
Human evidence [1] [2] [4] [9]Two randomized, placebo controlled ascending dose trials (28 and 49 days) in healthy adults: GH up 2 to 10 fold and IGF-1 up 1.5 to 3 fold. A separate study showed trough GH up 7.5 fold with pulsatility preserved.One randomized trial (117 adults after bowel resection, intravenous): time to first tolerated meal 25.3 versus 32.6 hours on placebo, not significant (p = 0.15). A separate study in 40 healthy men found that a single intravenous infusion releases GH; no IGF-1, body composition, or clinical outcome published.
Evidence grade [1] [4] [5]Human RCT (hormonal endpoints only, small trials, no clinical outcomes).Human RCT: one randomized, double blind, placebo controlled trial (117 adults after bowel surgery, intravenous) found no benefit. No randomized trial for the GH related uses it is sold for.
Safety signals [1] [4] [6]Injection site reactions, flushing, headache; FDA's Category 2 evaluation cited increased heart rate and a systemic vasodilatory reaction. Sustained IGF-1 elevation is untested long term.No safety signal versus placebo in the 7 day ileus trial (adverse events 87.5% versus 94.8%); FDA cited immunogenicity from aggregation and impurities.
Literature dosing [1] [4]Pharmacology trials only: single or repeated weekly or biweekly subcutaneous doses, with 30 or 60 ug/kg best tolerated.Not established; the only human trial used 0.03 mg/kg intravenously twice daily for up to 7 days.
Regulatory status [6] [7] [8]Never approved; development for HIV lipodystrophy and GH deficiency discontinued. 503A Category 2 in September 2023, now a withdrawn nomination.Never approved; development stopped after the ileus trial. 503A Category 2 in September 2023, 503A nominations withdrawn in 2024; ipamorelin acetate also remains in 503B Category 2.
Note: Neither was among the peptides reviewed by the Pharmacy Compounding Advisory Committee in July 2026. Both are prohibited under WADA section S2.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

CJC-1295 and Ipamorelin: grade, status, and cost
AttributeCJC-1295Ipamorelin
ClassSynthetic 29 amino acid GHRH(1-29) analog with four stabilizing amino acid substitutions and a drug affinity complex (maleimidoproprionic acid) that binds covalently to circulating albuminSynthetic pentapeptide growth hormone secretagogue; selective agonist at the ghrelin receptor (GHS-R1a)
What it isLong acting lab-made growth hormone releasing hormone: small randomized trials raised GH 2 to 10 fold and IGF-1 1.5 to 3 fold per dose; no compounding basis.Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit.
EvidenceEvidence: Human RCT evidenceEvidence: Human RCT evidence
FDA statusRegulatory: Nomination withdrawnRegulatory: Nomination withdrawn
CompoundingNot FDA approved for any use. FDA previously placed CJC-1295 in 503A Category 2, citing limited clinical data, peptide related impurities, and serious adverse events including increased heart rate and a systemic vasodilatory reaction. FDA now lists it under nominations withdrawn by the nominators, so it is in no 503A category and outside FDA's interim enforcement policy. At its December 4, 2024 meeting the Pharmacy Compounding Advisory Committee voted against placing any CJC-1295 form, with or without DAC, on the 503A bulks list, and it was not part of the July 2026 review. With no bulks list entry and no approved product, as of the last verification date a 503A pharmacy has no federal basis to compound it and no 503B pathway has been identified.Not FDA approved for any use. Ipamorelin was nominated for the 503A bulks list and placed in Category 2. FDA cited immunogenicity risk from aggregation or peptide related impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events, including a death, when it was given intravenously. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding ipamorelin free base or ipamorelin acetate to the 503A bulks list. FDA now lists ipamorelin acetate among 503A nominations withdrawn by the nominators, which puts it in no 503A category and outside FDA's interim policy. Ipamorelin acetate also remains in 503B Category 2, added September 29, 2023. It is not on the 503A bulks list, so as of the last verification date neither 503A pharmacies nor 503B outsourcing facilities have a federal basis to compound it.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesSubcutaneous injection (human trials and as sold)Subcutaneous injection (as sold, no human pharmacokinetic publication), Intravenous infusion (human ileus trial), Intranasal (anti-doping metabolite study only)
Typical costNot available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Last verified

Has CJC-1295 been tested directly against ipamorelin?

No published trial has compared CJC-1295 and ipamorelin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do CJC-1295 and ipamorelin cost?

Typical cost of CJC-1295 and Ipamorelin
DimensionCJC-1295Ipamorelin
Typical costNot available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Price detailCJC-1295 price by channelIpamorelin price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the CJC-1295 page and the Ipamorelin page.

Are CJC-1295 and ipamorelin combined?

CJC-1295 and ipamorelin are sold together in the premixed blend below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend page covers what is in each product, the evidence for each ingredient, and legal status.

Frequently asked questions

Which raises growth hormone more, CJC-1295 or ipamorelin?

No study has compared them. One injection of CJC-1295 raised mean GH 2 to 10 fold for 6 or more days and IGF-1 1.5 to 3 fold for 9 to 11 days. Ipamorelin released GH after a single intravenous infusion in a study of 40 healthy men, and in rats and pigs, but no published trial measures GH or IGF-1 after the subcutaneous injections used outside research. [1] [5] [9]

Is the CJC-1295 and ipamorelin blend proven?

No. No published trial has tested the combination. The rationale is that they act on different receptors (GHRH versus ghrelin), but efficacy and safety of the blend in humans are unknown. [1] [5]

Can a compounding pharmacy make either one legally?

No. FDA placed both on the 503A Category 2 list in September 2023; the 503A nominations were later withdrawn, and neither is on the bulks list or a component of an approved drug, so a 503A pharmacy has no federal basis to compound them. [6]

Is CJC-1295 without DAC the same drug?

No. The version sold as CJC-1295 without DAC (modified GRF 1-29) lacks the albumin binding group, lasts about 30 minutes instead of about a week, and has no published human trials under that name. [1] [3]

Are they allowed in sport?

No. Both are named in WADA section S2 and are prohibited at all times. [8]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006PubMed 16352683, 2006
  2. [2]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006PubMed 17018654, 2006
  3. [3]Jette L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005PubMed 15817669, 2005
  4. [4]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  5. [5]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
  6. [6]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA
  7. [7]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA
  8. [8]WADA Prohibited List, section S2 (GHRH analogues and growth hormone secretagogues, including CJC-1295 and ipamorelin)WADA
  9. [9]Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999PubMed 10496658, 1999

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). CJC-1295 vs ipamorelin: evidence, cost, and legality. https://peptideagent.ai/compare/cjc-1295-vs-ipamorelin
HTML link
<a href="https://peptideagent.ai/compare/cjc-1295-vs-ipamorelin">CJC-1295 vs ipamorelin: evidence, cost, and legality</a>, PeptideAgent, updated September 30, 2026.